Thirty-six healthy malaria-naive adults were randomly distributed into three dose blocks (10, 30 and 100 µg) and vaccinated with PfCS102 in combination with either Montanide ISA 720 or GSK proprietary Adjuvant System AS02A at days 0, 60, and 180.
After a preliminary safety evaluation of low dose AMA-1/AS01B (10 µg/0.5 mL) in 5 adults, 30 malaria-naïve adults were randomly allocated to receive full dose (50 µg/0.5 mL) of AMA-1/AS01B (n = 15) or AMA-1/AS02A (n = 15), followed by a malaria challenge.
The three Plasmodium species (P. falciparum, P. malariae and P. ovale) were randomly distributed amongst all children but not adults in the LIST and PT regions.
A sample of 185 vivax malaria patients was randomly selected from the HC database, and to minimize recall bias, the selection was limited to patients identified within the year before the study (i.e., July 2006 to July 2007).
Participants were randomly assigned to receive 1 of 3 oral regimens at their first episode of uncomplicated malaria and then for all subsequent episodes diagnosed during the study.
Others were randomly selected.
All seats were randomly assigned.
Instead, rewards were randomly distributed.
Households were randomly selected and sample sizes of each district were fixed on the basis of the population of the areas and the anticipated regional prevalence of malaria.
Again, malaria was not distributed randomly in 118 houses of this locality and the 101 cases of malaria which occurred in 2007 were concentrated in 47 households.
